Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 23;13(6):433–444. doi: 10.1093/jmcb/mjab018

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) (2021). Published by Oxford University Press on behalf of Journal of Molecular Cell Biology, CEMCS, CAS.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Combined inhibition of AKT and FAO overcomes endoxifen resistance. MCF7 cells and TRC were treated with vehicle, END (5 µM), MK (5 µM), ETO (10 µM), or the indicated combinations. (A and B) Cells treated for 72 h were analyzed with flow cytometry for cell cycles. (A) Cell cycle profiles were presented with population distribution in different phases indicated. (B) Average (triplicate) % sub-G1 (apoptotic) cells is presented with SD indicated. There are significant differences (P < 0.01) between treatments with triple drug combination and double drug combinations in both MCF7 cells and TRC and between MCF7 cells and TRC treated with END+MK or with triple drug combination. (C) Cells treated for 24 h were immunoblotted for cleaved caspase-3 and actin.